Notice of Intent_GA.pdf
PDF 72 KB Posted
- Solicitation number
- FDA-RFQ-26-133519
About this file
This is a Notice of Intent to issue a sole source contract. The Food and Drug Administration intends to award a sole source contract to the Georgia Drug and Narcotics Agency (GDNA) for investigative work under NAICS code 922120. The contract will be for a 12-month period of performance from the date of award and is authorized under 10 USC 2304(c)(5).
Interested firms must submit responses demonstrating their capability to provide investigative services within 7 days of the notice publication. All responses must be submitted via email to Nina.Montgomery@fda.hhs.gov, with a response deadline of April 3, 2026 at 10:00 a.m. EST. The government retains sole discretion to determine whether to compete the proposed contract based on responses received. This notice of intent is not itself a solicitation for competitive proposals.
View the file
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Notice of Intent #FDA-RFQ-26-133519
The Food and Drug Administration intends to make sole source awards to the following:
1. Georgia Drug and Narcotics Agency (GDNA)
They are all individual contracts for investigative work.
The period of performance will be for a total of 12 months from the date of award. The NAICS code for this action is 922120. This procurement is made under the authority of 10 USC 2304 (c)(5) - authorized by statute. This is a notice of intent to issue this solicitation on a sole source basis. This notice of intent is not a solicitation for competitive proposals. Any other firms desiring consideration must fully identify their interest and capability to provide this service or submit a proposal within 7 days to the individual listed. A determination by the government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. Responses to this notice must be sent via email to:
Nina.Montgomery@fda.hhs.gov. This notice will close on April 3, 2026 at 10am EST.
mailto:Nina.Montgomery@fda.hhs.gov
File details come from the government source that posted it. Updated .